Interações de Clopidogrel

CIBINQO is contraindicated in patients taking antiplatelet therapies, except for low-dose aspirin (≤81 mg daily), during the first 3 months of treatment [see Warnings and Precautions (5.7) , Drug Interactions (7.2) , and Clinical Pharmacology (12.2) ]. (bula de Abrocitinibe, Contraindicações)

…hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants • a history of traumatic or repeated epidural or spinal punctures • a history of spinal deformity or spinal surgery • optimal timing between… (bula de Apixabana, Advertência em caixa preta)

Antiplatelets: ticagrelor ↑ ticagrelor Coadministration with ticagrelor is not recommended due to potential increase in the risk of dyspnea, bleeding and other adverse events associated with ticagrelor. clopidogrel ↓ clopidogrel active metabolite Coadministration of REYATAZ (with or without ritonavir) and clopidogrel is not recommended. (bula de Atazanavir, Interações medicamentosas)

Coadministration of bupropion hydrochloride extended-release tablets (XL) with ticlopidine or clopidogrel is not recommended (7.1). (bula de Bupropiona, Interações medicamentosas)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (bula de Clopidogrel, Advertências e precauções)

Clopidogrel: Do not administer during KENGREAL infusion. (bula de Cangrelor, Interações medicamentosas)

As a precaution, avoid concomitant use of strong CYP2C19 inducers [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Clopidogrel, Advertências e precauções)

Celecoxib 100 mg twice daily was non-inferior to naproxen 375 to 500 mg twice daily and ibuprofen 600 to 800 mg three times daily for the composite endpoint of the Antiplatelet Trialists' Collaboration (APTC), which consists of cardiovascular death (including hemorrhagic death), non-fatal myocardial infarction, and non-fatal stroke [ see Clinical Studies (14.5)… (bula de Celecoxibe, Advertências e precauções)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (bula de Clopidogrel, Advertências e precauções)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (bula de Clopidogrel, Advertências e precauções)

Table 2: Oral drugs that can be administered concomitantly with Ferric Citrate Tablets Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Ferric Citrate Tablets and meals… (bula de Citrato férrico, Interações medicamentosas)

…hematomas in these patients include: use of indwelling epidural catheters concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants a history of traumatic or repeated epidural or spinal punctures a history of spinal deformity or spinal surgery optimal timing between the… (bula de Dabigatrana, Advertência em caixa preta)

…hematomas in these patients include: use of indwelling epidural catheters concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants a history of traumatic or repeated epidural or spinal punctures a history of spinal deformity or spinal surgery optimal timing between the… (bula de Edoxabana, Advertência em caixa preta)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (bula de Clopidogrel, Advertências e precauções)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (bula de Clopidogrel, Advertências e precauções)

Antiplatelets: ticagrelor ↑ ticagrelor Coadminstration with ticagrelor is not recommended. clopidogrel ↓ clopidogrel active metabolite Coadministration with clopidogrel is not recommended due to protential reduction of the antiplatelet activity of clopidogrel. (bula de Elvitegravir + cobicistate + entricitabina + tenofovir, Interações medicamentosas)

…hematomas in these patients include: Use of indwelling epidural catheters Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, and other anticoagulants A history of traumatic or repeated epidural or spinal punctures A history of spinal deformity or spinal surgery Optimal timing between… (bula de Enoxaparina, Advertência em caixa preta)

Avoid concomitant use of Plavix with omeprazole or esomeprazole because both significantly reduce the antiplatelet activity of Plavix [see Drug Interactions (7.1) ] . (bula de Clopidogrel, Advertências e precauções)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (bula de Clopidogrel, Advertências e precauções)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (bula de Clopidogrel, Advertências e precauções)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (bula de Clopidogrel, Advertências e precauções)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (bula de Clopidogrel, Advertências e precauções)

…in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, or other anticoagulants • a history of traumatic or repeated epidural or spinal puncture • a history of spinal deformity or spinal surgery • Optimal timing between… (bula de Fondaparinux, Advertência em caixa preta)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (bula de Clopidogrel, Advertências e precauções)

Anticoagulants and Antiplatelets Ticagrelor Contraindicated during and 2 weeks after TOLSURA treatment. (bula de Itraconazol, Interações medicamentosas)

As a precaution, avoid concomitant use of strong CYP2C19 inducers [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Clopidogrel, Advertências e precauções)

As a precaution, avoid concomitant use of strong CYP2C19 inducers [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Clopidogrel, Advertências e precauções)

Avoid concomitant use of Plavix with omeprazole or esomeprazole because both significantly reduce the antiplatelet activity of Plavix [see Drug Interactions (7.1) ] . (bula de Clopidogrel, Advertências e precauções)

Cardiovascular agents aliskiren, ticagrelor, vorapaxar clopidogrel ↑ aliskiren ↑ ticagrelor ↑ vorapaxar ↓ clopidogrel active metabolite Avoid concomitant use with PAXLOVID. cilostazol ↑ cilostazol Dosage adjustment of cilostazol is recommended. (bula de Nirmatrelvir + ritonavir, Interações medicamentosas)

Avoid concomitant use of Plavix with omeprazole or esomeprazole because both significantly reduce the antiplatelet activity of Plavix [see Drug Interactions (7.1) ] . (bula de Clopidogrel, Advertências e precauções)

Avoid concomitant use of Plavix with omeprazole or esomeprazole because both significantly reduce the antiplatelet activity of Plavix [see Drug Interactions (7.1) ] . (bula de Clopidogrel, Advertências e precauções)

…TR ial to Assess I mprovement in T herapeutic Outcomes by O ptimizing Platelet Inhibitio N with Prasugrel), patients with a history of TIA or ischemic stroke (>3 months prior to enrollment) had a higher rate of stroke on Effient (6.5%; of which 4.2% were thrombotic stroke and 2.3% were intracranial hemorrhage [ICH]) than on clopidogrel (1.2%; all thrombotic). (bula de Prasugrel, Contraindicações)

Avoid concomitant use of repaglinide with Plavix. (bula de Clopidogrel, Interações medicamentosas)

As a precaution, avoid concomitant use of strong CYP2C19 inducers [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Clopidogrel, Advertências e precauções)

As a precaution, avoid concomitant use of strong CYP2C19 inducers [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (bula de Clopidogrel, Advertências e precauções)

…in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants • a history of traumatic or repeated epidural or spinal punctures • a history of spinal deformity or spinal surgery • optimal timing between… (bula de Rivaroxabana, Advertência em caixa preta)

WARNING: BLEEDING RISK • BRILINTA, like other antiplatelet agents, can cause significant, sometimes fatal bleeding ( 5.1 , 6.1 ). (bula de Ticagrelor, Advertência em caixa preta)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (bula de Clopidogrel, Advertências e precauções)

CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (bula de Clopidogrel, Advertências e precauções)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (bula de Clopidogrel, Advertências e precauções)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (bula de Clopidogrel, Advertências e precauções)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (bula de Clopidogrel, Advertências e precauções)

Anticoagulants and antiplatelet drugs increase the risk of bleeding if administered prior to, during, or after Activase therapy. (bula de Alteplase, Interações medicamentosas)

Monitor patients for bleeding, including those receiving concomitant therapy with other drugs known to cause bleeding (e.g., anticoagulants, PDE3 inhibitors, NSAIDs, antiplatelet agents, selective serotonin reuptake inhibitors) [see Drug Interactions (7.3) , Clinical Pharmacology (12.3) ] . (bula de Anagrelida, Advertências e precauções)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (bula de Clopidogrel, Advertências e precauções)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (bula de Clopidogrel, Interações medicamentosas)

Opioids: Decreased exposure to clopidogrel. (bula de Clopidogrel, Interações medicamentosas)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (bula de Clopidogrel, Advertências e precauções)

Opioids: Decreased exposure to clopidogrel. (bula de Clopidogrel, Interações medicamentosas)

Opioids: Decreased exposure to clopidogrel. (bula de Clopidogrel, Interações medicamentosas)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (bula de Clopidogrel, Advertências e precauções)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (bula de Clopidogrel, Advertências e precauções)

Opioids: Decreased exposure to clopidogrel. (bula de Clopidogrel, Interações medicamentosas)

Opioids: Decreased exposure to clopidogrel. (bula de Clopidogrel, Interações medicamentosas)

Anticoagulants and Antiplatelet Drugs rivaroxaban cilostazol, coumarins, dabigatran Cilostazol: Concomitant administration of single doses of cilostazol 100 mg and ketoconazole 400 mg approximately doubled cilostazol concentrations and altered (increase/decrease) the concentrations of the active metabolites of cilostazol. (bula de Cetoconazol, Interações medicamentosas)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (bula de Clopidogrel, Advertências e precauções)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (bula de Clopidogrel, Advertências e precauções)

Other Antiplatelet Agents: Increases the risk of bleeding due to an additive effect. (bula de Clopidogrel, Interações medicamentosas)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (bula de Clopidogrel, Interações medicamentosas)

Opioids: Decreased exposure to clopidogrel. (bula de Clopidogrel, Interações medicamentosas)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (bula de Clopidogrel, Interações medicamentosas)

Dexlansoprazole, lansoprazole, and pantoprazole had less effect on the antiplatelet activity of Plavix than did omeprazole or esomeprazole [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3) ] . (bula de Clopidogrel, Interações medicamentosas)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (bula de Clopidogrel, Advertências e precauções)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (bula de Clopidogrel, Advertências e precauções)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (bula de Clopidogrel, Advertências e precauções)

Other Antiplatelet Agents: Increases the risk of bleeding due to an additive effect. (bula de Clopidogrel, Interações medicamentosas)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (bula de Clopidogrel, Interações medicamentosas)

Opioids: Decreased exposure to clopidogrel. (bula de Clopidogrel, Interações medicamentosas)

When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for VELETRI to increase the risk of bleeding. (bula de Epoprostenol, Interações medicamentosas)

Other Antiplatelet Agents: Increases the risk of bleeding due to an additive effect. (bula de Clopidogrel, Interações medicamentosas)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (bula de Clopidogrel, Interações medicamentosas)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (bula de Clopidogrel, Advertências e precauções)

Carbamazepine, felbamate, lamotrigine, topiramate, oxcarbazepine, lacosamide Antilipidemic agents Atorvastatin, fluvastatin, simvastatin Antiplatelets Ticagrelor Antiviral agents Efavirenz, lopinavir/ritonavir, indinavir, nelfinavir, ritonavir, saquinavir Fosamprenavir: phenytoin when given with fosamprenavir alone may decrease the concentration of amprenavir,… (bula de Fenitoína, Interações medicamentosas)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (bula de Clopidogrel, Advertências e precauções)

Opioids: Decreased exposure to clopidogrel. (bula de Clopidogrel, Interações medicamentosas)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (bula de Clopidogrel, Interações medicamentosas)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (bula de Clopidogrel, Advertências e precauções)

Carbamazepine, felbamate, lamotrigine, topiramate, oxcarbazepine, lacosamide Antiplatelets Ticagrelor Antilipidemic agents Atorvastatin, fluvastatin, simvastatin Antiviral agents Efavirenz, lopinavir/ritonavir, indinavir, nelfinavir, ritonavir, saquinavir Fosamprenavir: phenytoin when given with fosamprenavir alone may decrease the concentration of amprenavir,… (bula de Fosfenitoína, Interações medicamentosas)

O Ginkgo biloba pode aumentar o risco de sangramento quando tomado com medicamentos anticoagulantes ou antiagregantes plaquetários. (NCCIH, Ginkgo)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (bula de Clopidogrel, Advertências e precauções)

Opioids: Decreased exposure to clopidogrel. (bula de Clopidogrel, Interações medicamentosas)

Opioids: Decreased exposure to clopidogrel. (bula de Clopidogrel, Interações medicamentosas)

Opioids: Decreased exposure to clopidogrel. (bula de Clopidogrel, Interações medicamentosas)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (bula de Clopidogrel, Advertências e precauções)

Opioids: Decreased exposure to clopidogrel. (bula de Clopidogrel, Interações medicamentosas)

Opioids: Decreased exposure to clopidogrel. (bula de Clopidogrel, Interações medicamentosas)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (bula de Clopidogrel, Advertências e precauções)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (bula de Clopidogrel, Advertências e precauções)

The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin. (bula de Icosapente etílico, Advertências e precauções)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (bula de Clopidogrel, Advertências e precauções)

Dexlansoprazole, lansoprazole, and pantoprazole had less effect on the antiplatelet activity of Plavix than did omeprazole or esomeprazole [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3) ] . (bula de Clopidogrel, Interações medicamentosas)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (bula de Clopidogrel, Interações medicamentosas)

Opioids: Decreased exposure to clopidogrel. (bula de Clopidogrel, Interações medicamentosas)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (bula de Clopidogrel, Advertências e precauções)

Opioids: Decreased exposure to clopidogrel. (bula de Clopidogrel, Interações medicamentosas)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (bula de Clopidogrel, Interações medicamentosas)

Misoprostol does not exert clinically significant effects on the absorption, blood levels, and antiplatelet effects of therapeutic doses of aspirin. (bula de Misoprostol, Interações medicamentosas)

Consider the use of a parenteral antiplatelet agent in acute coronary syndrome patients requiring coadministration of morphine or other opioid agonists. (bula de Clopidogrel, Interações medicamentosas)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (bula de Clopidogrel, Advertências e precauções)

Opioids: Decreased exposure to clopidogrel. (bula de Clopidogrel, Interações medicamentosas)

Concomitant Treatment with CYP2B6 Inhibitors (e.g., ticlopidine or clopidogrel) can increase bupropion exposure. (bula de Naltrexona + bupropiona, Interações medicamentosas)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (bula de Clopidogrel, Advertências e precauções)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (bula de Clopidogrel, Interações medicamentosas)

Opioids: Decreased exposure to clopidogrel. (bula de Clopidogrel, Interações medicamentosas)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (bula de Clopidogrel, Advertências e precauções)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (bula de Clopidogrel, Advertências e precauções)

Opioids: Decreased exposure to clopidogrel. (bula de Clopidogrel, Interações medicamentosas)

Opioids: Decreased exposure to clopidogrel. (bula de Clopidogrel, Interações medicamentosas)

Opioids: Decreased exposure to clopidogrel. (bula de Clopidogrel, Interações medicamentosas)

Dexlansoprazole, lansoprazole, and pantoprazole had less effect on the antiplatelet activity of Plavix than did omeprazole or esomeprazole [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3) ] . (bula de Clopidogrel, Interações medicamentosas)

Opioids: Decreased exposure to clopidogrel. (bula de Clopidogrel, Interações medicamentosas)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (bula de Clopidogrel, Advertências e precauções)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (bula de Clopidogrel, Interações medicamentosas)

Opioids: Decreased exposure to clopidogrel. (bula de Clopidogrel, Interações medicamentosas)

DRUG INTERACTIONS Bleeding has been reported in patients treated with pentoxifylline extended-release tablets with or without concomitant NSAIDs, anticoagulants, or platelet aggregation inhibitors. (bula de Pentoxifilina, Interações medicamentosas)

Opioids: Decreased exposure to clopidogrel. (bula de Clopidogrel, Interações medicamentosas)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (bula de Clopidogrel, Advertências e precauções)

Opioids: Decreased exposure to clopidogrel. (bula de Clopidogrel, Interações medicamentosas)

Opioids: Decreased exposure to clopidogrel. (bula de Clopidogrel, Interações medicamentosas)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (bula de Clopidogrel, Advertências e precauções)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (bula de Clopidogrel, Interações medicamentosas)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (bula de Clopidogrel, Interações medicamentosas)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (bula de Clopidogrel, Advertências e precauções)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (bula de Clopidogrel, Advertências e precauções)

Opioids: Decreased exposure to clopidogrel. (bula de Clopidogrel, Interações medicamentosas)

Should serious bleeding that is not controlled by local pressure occur, discontinue any concomitant heparin or antiplatelet agents immediately and treat appropriately. (bula de Tenecteplase, Advertências e precauções)

Other Antiplatelet Agents: Increases the risk of bleeding due to an additive effect. (bula de Clopidogrel, Interações medicamentosas)

Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4 , 7.5 , 7.6 , 7.7) ]. (bula de Clopidogrel, Advertências e precauções)

Opioids: Decreased exposure to clopidogrel. (bula de Clopidogrel, Interações medicamentosas)

Opioids: Decreased exposure to clopidogrel. (bula de Clopidogrel, Interações medicamentosas)

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk ( 5.5 ). (bula de Trazodona, Advertências e precauções)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (bula de Clopidogrel, Interações medicamentosas)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (bula de Clopidogrel, Interações medicamentosas)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (bula de Clopidogrel, Interações medicamentosas)

Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (bula de Clopidogrel, Interações medicamentosas)

A vitamina E pode inibir a agregação plaquetária e a coagulação dependente de vitamina K, aumentando o risco de sangramento com medicamentos anticoagulantes e antiagregantes plaquetários. (NIH Office of Dietary Supplements, Vitamin E)

• Increased Risk of Bleeding : Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, other antiplatelet drugs, warfarin, or other drugs that affect coagulation may increase risk ( 5.3 ). (bula de Vortioxetina, Advertências e precauções)

Os suplementos de alho podem aumentar o risco de sangramento com anticoagulantes como a varfarina. (NCCIH, Garlic)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (bula de Clopidogrel, Interações medicamentosas)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (bula de Clopidogrel, Interações medicamentosas)

Repaglinide (CYP2C8 Substrates) The acyl-β-glucuronide metabolite of clopidogrel is a strong inhibitor of CYP2C8. (bula de Clopidogrel, Interações medicamentosas)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (bula de Clopidogrel, Interações medicamentosas)

If possible, assess the presence of drug-dependent antiplatelet antibodies. (bula de Etossuximida, Advertências)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (bula de Clopidogrel, Interações medicamentosas)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (bula de Clopidogrel, Interações medicamentosas)

Repaglinide (CYP2C8 Substrates) The acyl-β-glucuronide metabolite of clopidogrel is a strong inhibitor of CYP2C8. (bula de Clopidogrel, Interações medicamentosas)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (bula de Clopidogrel, Interações medicamentosas)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (bula de Clopidogrel, Interações medicamentosas)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (bula de Clopidogrel, Interações medicamentosas)

Repaglinide (CYP2C8 Substrates) The acyl-β-glucuronide metabolite of clopidogrel is a strong inhibitor of CYP2C8. (bula de Clopidogrel, Interações medicamentosas)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (bula de Clopidogrel, Interações medicamentosas)

Os suplementos de ômega-3 podem prolongar levemente o tempo de sangramento; a combinação com anticoagulantes como a varfarina justifica monitoramento, embora sangramento clinicamente significativo não tenha sido demonstrado de forma consistente. (NIH Office of Dietary Supplements, Omega-3 Fatty Acids)

Repaglinide (CYP2C8 Substrates) The acyl-β-glucuronide metabolite of clopidogrel is a strong inhibitor of CYP2C8. (bula de Clopidogrel, Interações medicamentosas)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (bula de Clopidogrel, Interações medicamentosas)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (bula de Clopidogrel, Interações medicamentosas)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (bula de Clopidogrel, Interações medicamentosas)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (bula de Clopidogrel, Interações medicamentosas)

Platelet aggregation inhibitor: ticagrelor ↑ ticagrelor Co-administration of PREZISTA/ritonavir and ticagrelor is not recommended. clopidogrel ↓ clopidogrel active metabolite Co-administration of PREZISTA/ritonavir and clopidogrel is not recommended due to potential reduction of the antiplatelet activity of clopidogrel. prasugrel ↔ prasugrel active metabolite… (bula de Darunavir, Interações medicamentosas)

Platelet aggregation inhibitor: ticagrelor ↑ ticagrelor Co-administration of PREZCOBIX or PREZCOBIX PED and ticagrelor is not recommended. clopidogrel ↓ clopidogrel active metabolite Co-administration of PREZCOBIX or PREZCOBIX PED with clopidogrel is not recommended due to the potential reduction of the antiplatelet activity of clopidogrel. prasugrel ↔ prasugrel… (bula de Darunavir + cobicistate, Interações medicamentosas)

Platelet Aggregation Inhibitors Clopidogrel: No clinically significant pharmacodynamic interactions were observed when clopidogrel was co-administered with nifedipine. (bula de Nifedipino, Interações medicamentosas)